MUC1-C Promotes the Suppressive Immune Microenvironment in Non-small Cell Lung Cancer
Overview
Authors
Affiliations
The cancer immune microenvironment is of importance for the effectiveness of immunotherapy; however, its dysregulation is poorly understood. The MUC1-C oncoprotein is aberrantly overexpressed in non-small cell lung cancer (NSCLC) and has been linked to the induction of PD-L1. The present work investigated the effects of targeting MUC1-C in an immuno-competent MUC1 transgenic (MUC1.Tg) mouse model. We show that Lewis Lung Carcinoma cells expressing MUC1-C (LLC/MUC1) exhibit upregulation of PD-L1 and suppression of interferon-γ (IFN-γ). In studies of LLC/MUC1 cells growing and as tumors in MUC1.Tg mice, treatment with the MUC1-C inhibitor, GO-203, was associated with the downregulation of PD-L1 and induction of IFN-γ. The results further demonstrate that targeting MUC1-C results in enhanced effector function of CD8+ tumor-infiltrating lymphocytes (TILs) as evidenced by increased expression of the activation marker CD69, the degranulation marker CD107α, and granzyme B. Notably, targeting MUC1-C was also associated with marked increases in TIL-mediated killing of LLC/MUC1 cells. Analysis of gene expression data sets further showed that overexpression of in NSCLCs correlates negatively with and , and that decreases in and are associated with poor clinical outcomes. These findings in LLC/MUC1 tumors and in NSCLCs indicate that MUC1-C→PD-L1 signaling promotes the suppression of CD8+ T-cell activation and that MUC1-C is a potential target for reprogramming of the tumor microenvironment.
Yang B, Kou R, Wang H, Wang A, Wang L, Sun S Int J Mol Med. 2024; 54(2).
PMID: 38963035 PMC: 11232663. DOI: 10.3892/ijmm.2024.5394.
Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors.
Chen T, Wang M, Chen Y, Liu Y Cancer Cell Int. 2024; 24(1):133.
PMID: 38622705 PMC: 11017638. DOI: 10.1186/s12935-024-03315-3.
The Role of MUC1 in Renal Cell Carcinoma.
Milella M, Rutigliano M, Lasorsa F, Ferro M, Bianchi R, Fallara G Biomolecules. 2024; 14(3).
PMID: 38540735 PMC: 10967890. DOI: 10.3390/biom14030315.
MUC1 and MUC16: critical for immune modulation in cancer therapeutics.
Chen X, Sandrine I, Yang M, Tu J, Yuan X Front Immunol. 2024; 15:1356913.
PMID: 38361923 PMC: 10867145. DOI: 10.3389/fimmu.2024.1356913.
Zhou Y, Li X, Guo Y, Wu Y, Yin L, Tu L MedComm (2020). 2024; 5(2):e484.
PMID: 38344400 PMC: 10857776. DOI: 10.1002/mco2.484.